Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody Drug Conjugate against Mutant and Wild Type c-KIT Positive Solid Tumors.

Abrams TJ, Connor A, Fanton CP, Cohen SB, Huber T, Miller K, Hong EE, Niu X, Kline J, Ison-Dugenny M, Harris S, Walker DB, Krauser KR, Galimi F, Wang Z, Ghoddusi M, Mansfield KG, Lee-Hoeflich ST, Holash J, Pryer N, Kluwe W, Ettenberg SA, Sellers WR, Lees E, Kwon P, Abraham JA, Schleyer S.

Clin Cancer Res. 2018 May 15. pii: clincanres.3795.2017. doi: 10.1158/1078-0432.CCR-17-3795. [Epub ahead of print]

PMID:
29764854
2.

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.

Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, Zhang C, Schnell C, Yang G, Zhang Y, Balbin OA, Barbe S, Cai H, Casey F, Chatterjee S, Chiang DY, Chuai S, Cogan SM, Collins SD, Dammassa E, Ebel N, Embry M, Green J, Kauffmann A, Kowal C, Leary RJ, Lehar J, Liang Y, Loo A, Lorenzana E, Robert McDonald E 3rd, McLaughlin ME, Merkin J, Meyer R, Naylor TL, Patawaran M, Reddy A, Röelli C, Ruddy DA, Salangsang F, Santacroce F, Singh AP, Tang Y, Tinetto W, Tobler S, Velazquez R, Venkatesan K, Von Arx F, Wang HQ, Wang Z, Wiesmann M, Wyss D, Xu F, Bitter H, Atadja P, Lees E, Hofmann F, Li E, Keen N, Cozens R, Jensen MR, Pryer NK, Williams JA, Sellers WR.

Nat Med. 2015 Nov;21(11):1318-25. doi: 10.1038/nm.3954. Epub 2015 Oct 19.

PMID:
26479923
3.

Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells.

Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, Daniel D, Hwang ES, Rugo HS, Coussens LM.

Cancer Cell. 2014 Nov 10;26(5):623-37. doi: 10.1016/j.ccell.2014.09.006. Epub 2014 Oct 16.

4.

Design, structure-activity relationship, and in vivo characterization of the development candidate NVP-HSP990.

McBride CM, Levine B, Xia Y, Bellamacina C, Machajewski T, Gao Z, Renhowe P, Antonios-McCrea W, Barsanti P, Brinner K, Costales A, Doughan B, Lin X, Louie A, McKenna M, Mendenhall K, Poon D, Rico A, Wang M, Williams TE, Abrams T, Fong S, Hendrickson T, Lei D, Lin J, Menezes D, Pryer N, Taverna P, Xu Y, Zhou Y, Shafer CM.

J Med Chem. 2014 Nov 13;57(21):9124-9. doi: 10.1021/jm501107q. Epub 2014 Nov 4.

PMID:
25368984
5.

Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.

Holderfield M, Lorenzana E, Weisburd B, Lomovasky L, Boussemart L, Lacroix L, Tomasic G, Favre M, Vagner S, Robert C, Ghoddusi M, Daniel D, Pryer N, McCormick F, Stuart D.

Cancer Res. 2014 Apr 15;74(8):2238-45. doi: 10.1158/0008-5472.CAN-13-1065-T. Epub 2014 Feb 12.

6.

CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells.

Strachan DC, Ruffell B, Oei Y, Bissell MJ, Coussens LM, Pryer N, Daniel D.

Oncoimmunology. 2013 Dec 1;2(12):e26968. Epub 2013 Dec 4.

7.

Mouse tumour models to guide drug development and identify resistance mechanisms.

Das Thakur M, Pryer NK, Singh M.

J Pathol. 2014 Jan;232(2):103-11. doi: 10.1002/path.4285. Review.

PMID:
24122209
8.

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.

Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD.

Nature. 2013 Feb 14;494(7436):251-5. doi: 10.1038/nature11814. Epub 2013 Jan 9.

9.

The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo.

Menezes DL, Taverna P, Jensen MR, Abrams T, Stuart D, Yu GK, Duhl D, Machajewski T, Sellers WR, Pryer NK, Gao Z.

Mol Cancer Ther. 2012 Mar;11(3):730-9. doi: 10.1158/1535-7163.MCT-11-0667. Epub 2012 Jan 12.

10.

The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo.

Loo D, Pryer N, Young P, Liang T, Coberly S, King KL, Kang K, Roberts P, Tsao M, Xu X, Potts B, Mather JP.

Mol Cancer Ther. 2007 Mar;6(3):856-65.

11.

CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.

Xin X, Abrams TJ, Hollenbach PW, Rendahl KG, Tang Y, Oei YA, Embry MG, Swinarski DE, Garrett EN, Pryer NK, Trudel S, Jallal B, Mendel DB, Heise CC.

Clin Cancer Res. 2006 Aug 15;12(16):4908-15.

12.

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL.

Mol Cancer Ther. 2004 Nov;3(11):1427-38.

13.

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.

Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM, Pryer NK.

Clin Exp Metastasis. 2003;20(8):757-66.

PMID:
14713109
14.

Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.

Pryer NK, Lee LB, Zadovaskaya R, Yu X, Sukbuntherng J, Cherrington JM, London CA.

Clin Cancer Res. 2003 Nov 15;9(15):5729-34.

15.

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.

Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM, Pryer NK.

Mol Cancer Ther. 2003 Oct;2(10):1011-21.

16.

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM.

Mol Cancer Ther. 2003 May;2(5):471-8.

18.

Cytosolic Sec13p complex is required for vesicle formation from the endoplasmic reticulum in vitro.

Pryer NK, Salama NR, Schekman R, Kaiser CA.

J Cell Biol. 1993 Feb;120(4):865-75.

19.

Brain microtubule-associated proteins modulate microtubule dynamic instability in vitro. Real-time observations using video microscopy.

Pryer NK, Walker RA, Skeen VP, Bourns BD, Soboeiro MF, Salmon ED.

J Cell Sci. 1992 Dec;103 ( Pt 4):965-76.

20.

Vesicle-mediated protein sorting.

Pryer NK, Wuestehube LJ, Schekman R.

Annu Rev Biochem. 1992;61:471-516. Review. No abstract available.

PMID:
1497318
22.

Effects of electric fields on fibroblast contractility and cytoskeleton.

Harris AK, Pryer NK, Paydarfar D.

J Exp Zool. 1990 Feb;253(2):163-76.

PMID:
2313246
23.

Video-enhanced differential interference contrast light microscopy.

Salmon T, Walker RA, Pryer NK.

Biotechniques. 1989 Jun;7(6):624-33. No abstract available.

PMID:
2631781
24.

Real-time observations of microtubule dynamic instability in living cells.

Cassimeris L, Pryer NK, Salmon ED.

J Cell Biol. 1988 Dec;107(6 Pt 1):2223-31.

25.

Dynamic instability of individual microtubules analyzed by video light microscopy: rate constants and transition frequencies.

Walker RA, O'Brien ET, Pryer NK, Soboeiro MF, Voter WA, Erickson HP, Salmon ED.

J Cell Biol. 1988 Oct;107(4):1437-48.

26.

Dynamic instability of microtubules.

Cassimeris LU, Walker RA, Pryer NK, Salmon ED.

Bioessays. 1987 Oct;7(4):149-54. Review. No abstract available.

PMID:
3318820
27.

Polarized microtubule gliding and particle saltations produced by soluble factors from sea urchin eggs and embryos.

Pryer NK, Wadsworth P, Salmon ED.

Cell Motil Cytoskeleton. 1986;6(6):537-48.

PMID:
2879641

Supplemental Content

Support Center